This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2008, p. 4388-4399, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00381-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States{triangledown}

Chris M. Pillar,* Mohana K. Torres, Nina P. Brown, Dineshchandra Shah, and Daniel F. Sahm

Eurofins Medinet Inc., Herndon, Virginia

Received 20 March 2008/ Returned for modification 6 June 2008/ Accepted 26 August 2008

Doripenem, a 1β-methylcarbapenem, is a broad-spectrum antibiotic approved for the treatment of complicated urinary tract and complicated intra-abdominal infections. An indication for hospital-acquired pneumonia including ventilator-associated pneumonia is pending. The current study examined the activity of doripenem against recent clinical isolates for the purposes of its ongoing clinical development and future longitudinal analysis. Doripenem and comparators were tested against 12,581 U.S. clinical isolates collected between 2005 and 2006 including isolates of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pneumoniae, Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. MICs (µg/ml) were established by broth microdilution. By MIC90, doripenem was comparable to imipenem and meropenem in activity against S. aureus (methicillin susceptible, 0.06; resistant, 8) and S. pneumoniae (penicillin susceptible, ≤0.015; resistant, 1). Against ceftazidime-susceptible Enterobacteriaceae, the MIC90 of doripenem (0.12) was comparable to that of meropenem (0.12) and superior to that of imipenem (2), though susceptibility of isolates exceeded 99% for all evaluated carbapenems. The activity of doripenem was not notably altered against ceftazidime-nonsusceptible or extended-spectrum β-lactamase screen-positive Enterobacteriaceae. Doripenem was the most potent carbapenem tested against P. aeruginosa (MIC90/% susceptibility [%S]: ceftazidime susceptible = 2/92%S, nonsusceptible = 16/61%S; imipenem susceptible = 1/98.5%S, nonsusceptible = 8/56%S). Against imipenem-susceptible Acinetobacter spp., doripenem (MIC90 = 2, 89.1%S) was twice as active by MIC90 as were imipenem and meropenem. Overall, doripenem potency was comparable to those of meropenem and imipenem against gram-positive cocci and doripenem was equal or superior in activity to meropenem and imipenem against Enterobacteriaceae, including β-lactam-nonsusceptible isolates. Doripenem was the most active carbapenem tested against P. aeruginosa regardless of β-lactam resistance.

* Corresponding author. Mailing address: Eurofins Medinet, Inc., Anti-Infectives Services, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171. Phone: (703) 480-2500. Fax: (703) 480-2670. E-mail: Chris.Pillar{at}eurofinsmedinet.com

{triangledown} Published ahead of print on 8 September 2008.

Antimicrobial Agents and Chemotherapy, December 2008, p. 4388-4399, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00381-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Bulik, C. C., Nicolau, D. P. (2009). In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 4352-4356 [Abstract] [Full Text]  
  • El Solh, A. A., Alhajhusain, A. (2009). Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 64: 229-238 [Abstract] [Full Text]  
  • Cirillo, I., Vaccaro, N., Turner, K., Solanki, B., Natarajan, J., Redman, R. (2009). Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers. J Clin Pharmacol 49: 798-806 [Abstract] [Full Text]  
  • Gelfand, M. S., Cleveland, K. O., Mazumder, S. A. (2009). Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63: 1297-1299 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»